The stocks on this list are not high-flying tech names, shoot-for-the-moon startups, or even high-growth names, but they are quietly crushing it for investors. Kroger NYSE: KR, Casey’s General Stores NASDAQ: CASY, and Autozone NYSE: AZO are all well-established businesses growing at steady and sustainable paces, driving reliable cash flow in good times and bad. The quality of their operations is clearly seen in their share prices, which are trending upward and outperforming the broad market in 2025. The out ...

Group 1 - The core viewpoint is that ACM Research, Inc. (NASDAQ: ACMR) is seen as a promising investment due to its growth potential in the wafer cleaning segment, which is crucial for the semiconductor supply chain [1] - The company is emerging as a significant player in its industry, indicating a positive outlook for future performance [1] Group 2 - The analysis is based on thorough research and analysis of financial statements, market trends, and upcoming events that may impact the company or industry [1]

Group 1 - Samuel Smith has extensive experience in dividend stock research and investment, having served as lead analyst and Vice President at notable firms [1] - He is a Professional Engineer and Project Management Professional, holding degrees in Civil Engineering & Mathematics and a Masters in Engineering with a focus on applied mathematics and machine learning [1] - Samuel leads the High Yield Investor investing group, collaborating with Jussi Askola and Paul R. Drake to balance safety, growth, yield, and value in investment strategies [2] Group 2 - High Yield Investor provides real-money core, retirement, and international portfolios, along with regular trade alerts and educational content [2] - The service includes an active chat room for investors to share insights and strategies [2]

Core Viewpoint - REGENXBIO Inc. announced that the FDA has accepted the Biologics License Application (BLA) for RGX-121, a potential one-time gene therapy for Mucopolysaccharidosis II (MPS II), with a target action date of November 9, 2025 [1][7]. Company Overview - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has developed a late-stage pipeline for rare and retinal diseases [6]. - The company has pioneered AAV gene therapy and aims to improve lives through its curative potential [6]. Product Details - RGX-121 (clemidsogene lanparvovec) is designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system, potentially providing a permanent source of the I2S protein [4]. - The therapy aims to address both neurodevelopmental and systemic effects of Hunter syndrome, which currently relies on weekly enzyme replacement therapy [2]. Regulatory Designations - RGX-121 has received multiple designations from the FDA, including Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) [2]. Commercialization Strategy - Following potential FDA approval, RGX-121 will be commercialized by NS Pharma, a subsidiary of Nippon Shinyaku, while REGENXBIO retains all rights and proceeds related to the potential sale of a Priority Review Voucher (PRV) [3].

Core Viewpoint - DraftKings' stock price has rebounded from a 9-month low, with expectations of reaching multi-year highs by the end of 2025 due to strong business performance, leverage building, and a healthy balance sheet [1] Financial Performance - DraftKings reported a 19.5% revenue growth in Q1, totaling $1.41 billion, driven by user engagement, new users, and acquisitions like Jackpocket [5] - Monthly unique players (MUP) increased by 28%, with a 20.1% rise in Sportsbook revenue, 14.5% in iGaming, and 45.7% in Other segments [5] - Adjusted earnings were $0.12, maintaining financial health despite a slight revenue miss compared to consensus [7] Market Opportunities - The acquisition of Jackpocket presents both challenges and opportunities, as it initially lowers revenue per user but offers potential for margin improvement over time [3] - The expected entry into Missouri and the growth potential of iGaming, which currently serves only 11% of the U.S. population, are significant growth drivers [4] Stock Forecast and Analyst Ratings - The 12-month stock price forecast for DraftKings is $55.04, indicating a 45.10% upside, with a Moderate Buy rating based on 28 analyst ratings [6] - Analysts have mixed responses, with some adjusting price targets, but the average target remains above current levels, suggesting potential for future gains [10][11] Trading Dynamics - The stock is showing bullish momentum, with critical resistance near $38.25, and could potentially retest all-time highs by late summer or early fall [12]

Financial Results - The company ended Q1 2025 with cash totaling $4.6 million, an increase from $3.7 million as of December 31, 2024 [1] - Research and development expenses for Q1 2025 were $0.6 million, down from $1.6 million in Q1 2024, primarily due to decreased manufacturing and consulting costs [3] - General and administrative expenses for Q1 2025 were $1.6 million, a decrease from $2.8 million in Q1 2024, attributed to lower professional fees and share-based compensation costs [4] - The company reported a net loss of $2.1 million or $0.11 per diluted share for Q1 2025, compared to a net loss of $4.4 million or $0.28 per diluted share for Q1 2024 [5] Operational Highlights - The company received positive regulatory guidance from the European Medicines Agency (EMA) for the ibezapolstat Phase 3 clinical trial program, aligning with FDA feedback [2] - New publications in the Journal of Antimicrobial Agents and Chemotherapeutics highlighted non-clinical studies that differentiate ibezapolstat from other antibiotics for treating C. difficile infection [2] - A new patent for DNA polymerase IIIC inhibitors was granted by the Japanese Patent Office, expiring in December 2039, supporting the development of ACX-375C [2] - The company closed a registered direct offering and private placement, raising gross proceeds of $1.1 million in March 2025 [2] Product Development - Ibezapolstat is the lead antibiotic candidate advancing to international Phase 3 clinical trials for treating C. difficile infection [7] - Ibezapolstat is a novel, orally administered antibiotic with a Gram-Positive Selective Spectrum (GPSS®) that spares beneficial gut microbiota while targeting C. difficile [7] - The CDC has designated C. difficile as an urgent threat, emphasizing the need for new antibiotics [7] - The company’s R&D pipeline includes antibiotic candidates targeting Gram-positive bacteria, including MRSA and VRE [8]

SANTA CLARA, Calif., May 13, 2025 /PRNewswire/ -- Tuya Inc. ("Tuya" or the "Company") (NYSE: TUYA; HKEX: 2391), a global leading AI cloud platform service provider, today announced that MSCI has upgraded its Environmental, Social, and Governance (ESG) rating to 'AA' from 'A'. This upgrade recognizes Tuya's efforts to build a more sustainable and responsible business and places Tuya among the ESG leaders in its sector.MSCI, a leading provider of research-driven indices and analytics, reviewed companies in th ...

Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a ...

SANTA CLARA, Calif., May 13, 2025 /PRNewswire/ -- Tuya Inc. ("Tuya" or the "Company") (NYSE: TUYA; HKEX: 2391), a global leading AI cloud platform service provider, today announced that it will report its first quarter 2025 unaudited financial results after the market closes on Tuesday, May 20, 2025.Tuya's management will hold a conference call at 08:30 P.M. Eastern Time on Tuesday, May 20, 2025 (08:30 A.M. Hong Kong Time on Wednesday, May 21, 2025) to discuss the financial results. In advance of the confer ...

First product validated at the VALOR lab's new RF-shielded anechoic chamberCHANDLER, Ariz., May 13, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) today announced that Metanoia Communications Inc.'s JURA Open Radio Unit (O-RU) has successfully completed end-to-end over-the-air (OTA) validation at the VIAVI Automated Lab-as-a-Service (VALOR™). It is the first product to be validated at the lab's new RF-shielded anechoic chamber to ensure compliance with O-RAN and 3GPP specifications. Me ...